Company intelligence / Profile preview

7TM Pharma

Ownership: Private
Development stage: Phase 1

Overview

The company had several drug candidates in development for metabolic disorders and obesity, including TM30339 (a Y4 selective agonist) and TM38837 (a peripherally acting CB1 antagonist). As of 2025, most programs appear to be discontinued or pending.

Therapeutic areas: PulmonologyEndocrinologyCardiovascularMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

obinepitide

Unknown

2 more assets in the full pipeline.

Request access →

Partnerships

OSI Pharmaceuticals

Beyond the preview

Go deeper on 7TM Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7TM Pharma.

Explore the full profile